Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in MRD-positive acute myeloid leukemia after allogeneic stem cell transplantation
2019-000136-26Phase 2Terminated
- Sponsor
- Friedrich Schiller University Jena
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Friedrich Schiller University Jena. Primary endpoint: Leukemia-free survival. Started Oct 2019; status: terminated.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-000136-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000136-26.